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Abstract 
Background: Preeclampsia is one of the major contributors to morbidity and mortality in 
the mother and fetus. Imbalance of pro-angiogenic factors and anti-angiogenic factor has 
important role in pathogenesis of preeclampsia,include PIGF and VEGF. Provision VEGF 
Recombinant is suspected decreased Sflt 1. This study aims to prove the effect of VEGF 
Recombinant 121  in expression  VEGFR 1 in placenta of preeclampsia-model mice (mus 
musculus). 
 
Methods: This analytic experimental study perform in 30 health mice (mus musculus) that 
pregnant for 16 days, with 20-25 gram bodyweight, to analyze in 3 groups, that are 10 
normal pregnant mice (k(-)), 10 preeclampsia mice (K(+)), 10 preeclampsia that treat by 
VEGF Recombinant 121 (P). Sampling have done in all mice serum disentrigfugated at 
room temperature with a force of 3000 grams per 10 minutes and then stored at 80 ° C prior 
to measurement,except 1 sample had unable to analiyzed. Results from each sample 
assessed semiquantitatively according Remmele-modified  methods, where the Remmele 
index scale (immuno reactive score / IRS) is the result of multiplying the percentage of 
immunoreactive cells score to the color intensity immunoreactive cells score. Data analysis 
was done using Kruskal Wallis and Mann Whitney performed by SPSS Software Package 
for Social Science) 21. 
 
Results: Expression VEGFR 1 mean of group K(-) is 0.80+1.13/µm2, K(+) groups is 
3.50+1.43 /µm2, and (P) groups is 1.30+ 0.70 /µm2. We found significant differences in 
normal groups compare to preeclampsia groups (p=0.001*), and also in preeclampsia group 
compare to treatment groups (p=0.000*). But in preeclampsia groups compare to normal 
groups there is no significant differences (p=1.000). So we can see that VEGF Recombinant 
121 is effective to reduce expression VEGFR 1 in placenta of  preeclampsia mice models 
(mus musculus). 
 
Conclusion: There are proven significant effectiveness of treatment VEGF Recombinant 
121  in expression  VEGFR 1 in placenta of  preeclampsia mice models (mus musculus). 
 
 
